Advertisement
News
Advertisement

Millennium submits supplemental NDAs on cancer drug

Tue, 04/26/2011 - 9:38am
Mass High Tech: The Journal of New England Technology

Cambridge-based cancer pharmaceutical company Millennium: The Takeda Oncology Company and parent Takeda Pharmaceutical Co. Ltd. of Osaka, Japan, said they have submitted two supplemental new drug applications (NDAs) for Velcade, a cancer treatment, to the U.S. Food and Drug Administration.

The first supplemental NDA seeks to add a subcutaneous route of administration for the drug, and the second is for Velcade in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma. The drug currently is approved for intravenous use in patients with multiple myeloma and those with mantle cell lymphoma.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading